Bausch+Lomb Results Presentation Deck
Pipeline and Upcoming Milestones¹
Surgical
Product
en Vista Envy TM
en Vista® Trifocal IOL (Intraocular Lens)
Stable Visc TM Cohesive OVD
en Vista Aspire TM
en Vista® Extended Range Monofocal IOL
en Vista Dynamic ™
en Vista® Extended Depth of Focus IOL
Lux Premium IOL
Next Generation Surgical Platform
System 202x
eye TELLIGENCE® Digital Platform
3D icroscope
Teneo ™M Excimer Laser
BAUSCH + LOMB
Status
Canadian study completed enrollment in 1Q22;
U.S. study completed enrollment in 2Q22
Clinical Study Report completed 2Q22;
FDA submission filed early 3Q22
US and Canada submission planned for 4Q22
EU submission planned for 2Q23
Clinical study to begin 3Q23
Launched in Europe
Alpha prototype build and test underway
Beta software release at AAO October 2022;
Software as Medical Device (SaMD)
documentation ongoing
Approval expected 2023
Enrollment completed for myopia study
Enrolled first patient 3Q22 in hyperopia study
1. See slide 1 for further information on forward-looking statements.
Upcoming Milestone
Expect Canadian launch 2023;
Expect US and EU launch 2024
Expect US approval 4Q22
Expect US and Canada launch 2H23
Expect 2025/2026 launch
Continued expansion of platform expected in
2023
Beta prototyping expected 1Q23
US commercial release expected 1Q23
Launch expected in 2023
Expected myopia launch in U.S. in 2023
27View entire presentation